Theravance Biopharma, Inc. Deferred Tax Assets, Deferred Income
Theravance Biopharma, Inc. (TBPH) had Deferred Tax Assets, Deferred Income of $0 as of 2014-12-31, per its 10-K filed 2015-03-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2015-03-13
- 2014-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2013-12-31: Deferred Tax Assets, Deferred Income $3.02M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-13 |
| 2013-12-31 | $3.02M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |